Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against hard targets and undruggable proteins
Small molecule drugs targeting novel proteins involved in the regulation of mRNA translation
The Selectivity of Translation Biology
Cells control protein translation using multiple selective mechanisms, offering novel intervention points. Modulation of translation is therefore possible with highly selective drugs.
mRNA translation modulators
A novel target space
Selective translation modulators with novel mechanisms of action elucidated by Anima’s proprietary technologies
Translation Control Therapeutics platform
Our proprietary platform controls mRNA Translation Biology
Anima’s science is using fluorescently labeled tRNA pairs to generate FRET signals, light pulses emitted from the ribosomes to visualize the translation of any protein of interest and identify selective translation modulators
mRNA Translation Modulators Pipeline
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), Oncology (c-Myc translation inhibitors and K-Ras translation inhibitors), Neuroscience (mHTT translation inhibitors, expanded to a broader strategy against Repeat Associated Diseases) and Infectious diseases (RSV viral proteins translation inhibitors)
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact [email protected].
17 Scientific Collaborations
15 Peer Reviewed Publications
Nucleic Acids Res. 2020 ;46(6):e32
Eur J Cell Biol (2018) ; 97 : 168-179.
Integr Biol (2016); 8 :645-53
J Cell Biol. 2016; 23;213(4):451-62.
News & Events
DMCCB Basel Symposium 2021 on Targeting RNA by Small Molecules
When: Feb. 4th, 2021
Anima Biotech has been invited to present at the DMCCB Basel Symposium 2021 on Targeting RNA by Small Molecules online event. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will be giving a presentation, titled, “Targeting mRNA translation in drug discovery without ‘shooting the messenger’" followed by a short question and answer session.
7th Annual LSX World Congress
When: Feb. 1st, 2021 - Feb. 5th, 2021
Anima Biotech has been invited to participate in a panel discussion at the 7th Annual LSX World Congress. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will serve as an expert on a panel titled, “Early-Stage Partnering for Broad Platform Companies.” The panel will speak to the compelling scientific innovation and record-breaking IPOs and financings that have led to a resurgence in the appeal and valuations of broad platform biopharma companies and how platform companies can advance their portfolio development and partnering strategies to fulfill their promise and justify investor confidence.
3rd Annual RNA-Targeted Drug Discovery Conference
When: Dec. 8th, 2020 - Dec. 10th, 2020
Anima Biotech has been invited to present and participate in multiple sessions during the 3rd Annual RNA-Targeted Drug Discovery Conference, between Dec. 8-10, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” and will also serve on an expert panel, titled, “From Theory to Reality: How to Target RNA Biology with Small Molecule Approaches.” Iris Alroy, VP of R&D, will also participate in an expert Q&A session.